CalciMedica is trading 5.33% lower at $1.42, with broader biotech weakness the clearest contemporaneous context. - Biotech ETF XBI is down 2.04% during the session amid cautious sentiment; no verified volume information indicates unusual activity. - No new company-specific announcement explaining the October 8 move surfaced in the search. A September 30 filing enables up to $25 million in at-the-market stock sales, potentially raising dilution concerns, but available evidence does not establish it as the cause.